HRP20192160T1 - Vezujući proteini serumskog albumina - Google Patents
Vezujući proteini serumskog albumina Download PDFInfo
- Publication number
- HRP20192160T1 HRP20192160T1 HRP20192160TT HRP20192160T HRP20192160T1 HR P20192160 T1 HRP20192160 T1 HR P20192160T1 HR P20192160T T HRP20192160T T HR P20192160TT HR P20192160 T HRP20192160 T HR P20192160T HR P20192160 T1 HRP20192160 T1 HR P20192160T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- protein
- amino acid
- construct
- seq
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 102000007562 Serum Albumin Human genes 0.000 title 1
- 108010071390 Serum Albumin Proteins 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 150000005829 chemical entities Chemical class 0.000 claims 9
- 108060003951 Immunoglobulin Proteins 0.000 claims 7
- 102000018358 immunoglobulin Human genes 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (17)
1. Polipeptid, protein, konstrukt, spoj ili drugi kemijski entitet koji sadrže aminokiselinsku sekvencu Alb-23 kako je navedeno u SEQ ID NO: 1 ili varijantu Alb-23, pri čemu je Alb-23 ili varijanta Alb-23 usmjerena protiv ljudskog serumskog albumina, i jednu ili više drugih aminokiselinskih sekvenci, vezujućih domena, vezujućih jedinica ili drugih dijelova ili kemijskih entiteta, prikladno međusobno povezanih bilo izravno ili po izboru putem jedne ili više odgovarajućih poveznica ili razmaknica, pri čemu navedena varijanta Alb-23 sadrži:
(i) motiv aminokiseline GP na položajima 44 i 45;
(ii) motiv aminokiseline SKN na položajima 74 do 76;
(iii) CDR1 koji je aminokiselinska sekvenca SFGMS kako je navedeno u SEQ ID NO:29;
(iv) CDR2 koji je aminokiselinska sekvenca SISGSGSDTLYADSVKG kako je navedeno u SEQ ID NO:30;
(v) CDR3 koji je aminokiselinska sekvenca GGSLSR kako je navedeno u SEQ ID NO:31;
i koja poželjno također sadrži
(vi) G na položaju 16; i/ili (vii) R na položaju 83 i poželjno oba G na položaju 16 i R na položaju 83;
pri čemu navedena varijanta Alb-23 nadalje sadrži između 1 i 7, kao što je između 1 i 5 daljnjih razlika u aminokiselinama sa sekvencom navedenom u SEQ ID NO:1; te pri čemu navedena varijanta Alb-23 ima poboljšanu toplinsku stabilnost određenu mjerenjem Tm u usporedbi s Alb-8 koja ima sekvencu:
2. Polipeptid, protein, konstrukt, spoj ili drugi kemijski entitet prema patentnom zahtjevu 1, naznačeni time što sadrže ili uglavnom sadrže aminokiselinsku sekvencu Alb-23 kako je navedeno u SEQ ID NO:1 i jednu ili više drugih aminokiselinskih sekvenci, domena, vezujućih jedinica ili drugih dijelova ili kemijskih entiteta, prikladno međusobno vezanih ili izravno ili po izboru preko jedne ili više odgovarajućih poveznica ili razmaknica.
3. Polipeptid, protein, konstrukt, spoj ili drugi kemijski entitet prema patentnom zahtjevu 1 ili 2, naznačeni time što navedena jedna ili više aminokiselinskih sekvenci, domena, vezivnih jedinica ili drugih dijelova ili kemijskih entiteta predstavljaju jednu ili više terapeutskih sekvenci aminokiselina, domena, vezivnih jedinica, skupina ili entiteta.
4. Polipeptid, protein ili konstrukt u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačeni time što jedna ili više drugih aminokiselinskih sekvenci, domena, vezivnih jedinica ili drugih dijelova ili kemijskih entiteta predstavljaju jednu ili više imunoglobulinskih pojedinačnih varijabilnih domena.
5. Polipeptid, protein ili konstrukt prema patentnom zahtjevu 4, naznačeni time što su jedna ili više drugih aminokiselinskih sekvenci, domena, vezivnih jedinica ili drugih dijelova ili kemijskih entiteta predstavljaju jedan ili više VHH-ova, humanizirani VHH-ovi ili kameliziran VH-ovi.
6. Polipeptid, protein ili konstrukt prema patentnom zahtjevu 4 ili 5, naznačeni time što najmanje jedna od imunoglobulinskih pojedinačnih varijabilnih domena sadrži najmanje dva disulfidna mosta.
7. Polipeptid, protein ili konstrukt prema patentnom zahtjevu 5 ili 6, naznačeni time što najmanje jedna od VHH, humaniziranih VHH, kameliziranih VH ili imunoglobulinskih pojedinačnih varijabilnih domena je VHH razreda I.
8. Polipeptid, protein ili konstrukt u skladu s bilo kojim od patentnih zahtjeva 4 do 7, naznačeni time što je najmanje jedna imunoglobulinska pojedinačna varijabilna domena usmjerena protiv c-met.
9. Polipeptid, protein ili konstrukt prema patentnom zahtjevu 8, naznačeni time što najmanje jedna imunoglobulinska pojedinačna varijabilna domena koja je usmjerena protiv c-met sadrži dva disulfidna mosta.
10. Polipeptid, protein ili konstrukt prema patentnom zahtjevu 8 ili 9, naznačeni time što navedena imunoglobulinska pojedinačna varijabilna domena protiv c-met je 4E09 kako je navedeno u SEQ ID NO: 12 ili varijanta 4E09.
11. Polipeptid, protein ili konstrukt u skladu s bilo kojim od patentnih zahtjeva 8 do 10, naznačeni time što navedena pojedinačna varijabilna domena imunoglobulina protiv c-met je A00790105 kako je navedeno u SEQ ID NO: 19.
12. Polipeptid, protein ili konstrukt u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačeni time što je A00790105-9GS-Alb23 kako je navedeno u SEQ ID NO: 23 ili polipeptid koji ima najmanje 80%, kao što je najmanje 85%, na primjer najmanje 90%, kao što je najmanje 95% ili više identičnosti sekvence sa SEQ ID NO: 23.
13. Farmaceutski pripravak naznačen time što sadrži najmanje jedan polipeptid, protein, konstrukt ili spoj u skladu s bilo kojim od zahtjeva 1 do 12, i po izboru najmanje jedan farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćnu tvar.
14. Farmaceutski pripravak prema patentnom zahtjevu 13, naznačen time što je za primjenu na način koji omogućuje ulazak u cirkulaciju polipeptida, proteina, konstrukta, spoja ili drugog kemijskog entiteta.
15. Nukleotidna sekvenca ili nukleinska kiselina naznačena time što kodira polipeptid, protein ili konstrukt prema bilo kojem od patentnih zahtjeva 1 do 12.
16. Stanica domaćina naznačena time što sadrži i može eksprimirati nukleotidnu sekvencu ili nukleinsku kiselinu u skladu s patentnim zahtjevom 15.
17. Postupak za pripremu polipeptida, proteina ili konstrukta prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što postupak sadrži uzgajanje ili održavanje stanice domaćina prema zahtjevu 16 pod takvim uvjetima da navedena stanica domaćina proizvodi ili eksprimira navedeni polipeptid, protein ili konstrukt, i proizvoljno nadalje sadrži izoliranje tako proizvedenog polipeptida, proteina ili konstrukta.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161500464P | 2011-06-23 | 2011-06-23 | |
EP12727658.2A EP2723771B1 (en) | 2011-06-23 | 2012-06-14 | Serum albumin binding proteins |
PCT/EP2012/061304 WO2012175400A1 (en) | 2011-06-23 | 2012-06-14 | Serum albumin binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20192160T1 true HRP20192160T1 (hr) | 2020-02-21 |
Family
ID=46298413
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170535TT HRP20170535T4 (hr) | 2011-06-23 | 2012-06-25 | Tehnike za predviđanje, otkrivanje i smanjenje nespecifičnog ometanja proteina u testovima koji uključuju imunoglobulinske jednostruke varijabilne domene |
HRP20192160TT HRP20192160T1 (hr) | 2011-06-23 | 2019-11-29 | Vezujući proteini serumskog albumina |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170535TT HRP20170535T4 (hr) | 2011-06-23 | 2012-06-25 | Tehnike za predviđanje, otkrivanje i smanjenje nespecifičnog ometanja proteina u testovima koji uključuju imunoglobulinske jednostruke varijabilne domene |
Country Status (17)
Country | Link |
---|---|
US (2) | US9573992B2 (hr) |
EP (3) | EP2723771B1 (hr) |
JP (3) | JP6324887B2 (hr) |
CN (2) | CN103619878B (hr) |
AU (1) | AU2012271974B2 (hr) |
CA (1) | CA2839779C (hr) |
CY (1) | CY1122691T1 (hr) |
DK (1) | DK2723771T3 (hr) |
ES (1) | ES2759936T3 (hr) |
HR (2) | HRP20170535T4 (hr) |
HU (1) | HUE047238T2 (hr) |
IN (1) | IN2014CN00414A (hr) |
LT (1) | LT2723771T (hr) |
PL (1) | PL2723771T3 (hr) |
PT (1) | PT2723771T (hr) |
SI (1) | SI2723771T1 (hr) |
WO (1) | WO2012175400A1 (hr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
PL2723771T3 (pl) * | 2011-06-23 | 2020-04-30 | Ablynx Nv | Białka wiążące albuminy surowicy |
KR20220114104A (ko) * | 2011-06-23 | 2022-08-17 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
EP2747783B1 (en) * | 2011-09-30 | 2017-06-14 | Ablynx N.V. | Biological materials related to c-met |
WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
MX2016014926A (es) | 2014-05-16 | 2017-05-09 | Ablynx Nv | Dominios variables de inmunoglobulina mejorados. |
WO2015173342A1 (en) | 2014-05-16 | 2015-11-19 | Ablynx Nv | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
BR122018009619B1 (pt) | 2014-05-16 | 2024-01-02 | Ablynx N.V | Domínios variáveis de imunoglobulina aperfeiçoados |
NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
WO2016097313A1 (en) | 2014-12-19 | 2016-06-23 | Ablynx N.V. | Cysteine linked nanobody dimers |
AU2016210835B2 (en) | 2015-01-29 | 2021-01-21 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders |
EP3932428A1 (en) | 2015-05-21 | 2022-01-05 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
NO2768984T3 (hr) | 2015-11-12 | 2018-06-09 | ||
EP3974449A1 (en) | 2015-11-13 | 2022-03-30 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
WO2017087587A1 (en) | 2015-11-18 | 2017-05-26 | Merck Sharp & Dohme Corp. | PD1/CTLA4 Binders |
KR102194188B1 (ko) | 2015-11-18 | 2020-12-24 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
CA3004900C (en) | 2015-11-18 | 2021-08-10 | Merck Sharp & Dohme Corp. | Ctla4 binders |
US11332519B2 (en) | 2015-11-18 | 2022-05-17 | Ablynx N.V. | Serum albumin binders |
TN2018000180A1 (en) | 2015-11-27 | 2019-10-04 | Ablynx Nv | Polypeptides inhibiting cd40l |
US10100106B2 (en) | 2016-05-20 | 2018-10-16 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
PL3475699T3 (pl) | 2016-06-23 | 2022-09-26 | Ablynx N.V. | Ulepszone oznaczenia farmakokinetyczne dla pojedynczych domen zmiennych immunoglobuliny |
BR112019010061A2 (pt) | 2016-11-16 | 2019-08-13 | Ablynx Nv | polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta |
US11414480B2 (en) | 2016-12-07 | 2022-08-16 | Ablynx N.V. | Serum albumin binding immunoglobulin single variable domains |
CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
CN117327175A (zh) | 2017-01-17 | 2024-01-02 | 埃博灵克斯股份有限公司 | 改进的血清白蛋白结合物 |
WO2018134235A1 (en) * | 2017-01-17 | 2018-07-26 | Ablynx Nv | Improved serum albumin binders |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
SG11201908154RA (en) | 2017-03-31 | 2019-10-30 | Ablynx Nv | Improved immunogenicity assays |
AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
AU2018347582A1 (en) | 2017-10-13 | 2020-05-07 | Harpoon Therapeutics, Inc. | Trispecific proteins and methods of use |
US10927180B2 (en) | 2017-10-13 | 2021-02-23 | Harpoon Therapeutics, Inc. | B cell maturation antigen binding proteins |
EP3758755A1 (en) * | 2018-02-26 | 2021-01-06 | Ablynx N.V. | Improved nucleotide sequences encoding peptide linkers |
KR20210086623A (ko) | 2018-09-25 | 2021-07-08 | 하푼 테라퓨틱스, 인크. | Ddl3 결합 단백질 및 사용 방법 |
CN110964107B (zh) * | 2018-09-30 | 2022-08-09 | 苏州康宁杰瑞生物科技有限公司 | Met结合分子、其组合和用途 |
CN111138537B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 一种抗人血清白蛋白抗体片段、制备方法和应用 |
CN111138536B (zh) * | 2018-11-06 | 2021-07-09 | 瑞阳(苏州)生物科技有限公司 | 抗人血清白蛋白单域抗体的制备及其应用 |
SG11202111671QA (en) * | 2019-05-15 | 2021-11-29 | Crescendo Biologics Ltd | Binding molecules |
CN114980923A (zh) | 2019-12-06 | 2022-08-30 | 艾伯霖克斯公司 | 包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽 |
EP4069733A1 (en) | 2019-12-06 | 2022-10-12 | Ablynx N.V. | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFalpha AND IL-23 |
TW202136302A (zh) | 2019-12-09 | 2021-10-01 | 比利時商艾伯霖克斯公司 | 包含靶向il-13及tslp之免疫球蛋白單可變域的多肽 |
CN110988361B (zh) * | 2019-12-13 | 2020-09-18 | 山东民康生物科技有限公司 | 人血清白蛋白去除试剂盒 |
WO2021168303A1 (en) | 2020-02-21 | 2021-08-26 | Harpoon Therapeutics, Inc. | Flt3 binding proteins and methods of use |
AU2021246890A1 (en) | 2020-03-30 | 2022-12-01 | Ablynx Nv | Method for the production and purification of multivalent immunoglobulin single variable domains |
KR20230074527A (ko) | 2020-09-25 | 2023-05-30 | 아블린쓰 엔.브이. | Il-13 및 ox40l을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
CN112142846B (zh) * | 2020-10-10 | 2022-07-08 | 西北大学 | Aox特异性抗体组合及其制备方法和用途 |
EP4237438A1 (en) * | 2020-10-27 | 2023-09-06 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of gdf15 and use thereof |
EP4262985A1 (en) | 2020-12-18 | 2023-10-25 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
US20240092919A1 (en) | 2020-12-18 | 2024-03-21 | Ablynx N. V. | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
US11897951B2 (en) | 2020-12-18 | 2024-02-13 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α |
EP4288461A1 (en) * | 2021-07-14 | 2023-12-13 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion polypeptides for metabolic disorders |
TW202340240A (zh) * | 2021-11-17 | 2023-10-16 | 大陸商江蘇先聲藥業有限公司 | 多特異性抗體及其藥物用途 |
WO2023111266A1 (en) | 2021-12-17 | 2023-06-22 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
WO2023134742A1 (zh) * | 2022-01-14 | 2023-07-20 | 浙江道尔生物科技有限公司 | 一种三靶点抗肿瘤药物、其制备方法及其应用 |
US20240109965A1 (en) | 2022-06-14 | 2024-04-04 | Ablynx N.V. | Immunoglobulin single variable domains targeting t cell receptor |
WO2023242371A1 (en) | 2022-06-15 | 2023-12-21 | argenx BV | Ph-dependent hsa-binding molecules and methods of use |
WO2024023271A1 (en) | 2022-07-27 | 2024-02-01 | Ablynx Nv | Polypeptides binding to a specific epitope of the neonatal fc receptor |
WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5608039A (en) | 1990-10-12 | 1997-03-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Single chain B3 antibody fusion proteins and their uses |
PT1498427E (pt) | 1992-08-21 | 2010-03-22 | Univ Bruxelles | Imunoglobulinas desprovidas de cadeias leves |
EP0698097B1 (en) | 1993-04-29 | 2001-08-16 | Unilever N.V. | Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
FR2846667B1 (fr) | 2002-11-06 | 2004-12-31 | Pasteur Institut | Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives |
EP2390268B1 (en) | 2002-11-08 | 2017-11-01 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
EP2390270A1 (en) | 2003-01-10 | 2011-11-30 | Ablynx N.V. | Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation |
PT1773885E (pt) * | 2004-08-05 | 2010-07-21 | Genentech Inc | Antagonistas anti-cmet humanizados |
MX363423B (es) * | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
WO2006129843A2 (en) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Bispecific capturing molecule |
WO2006129828A2 (en) | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Target substance capturing molecule |
EP1976991A1 (en) | 2006-01-24 | 2008-10-08 | Domantis Limited | Fusion proteins that contain natural junctions |
EP2004693B1 (en) * | 2006-03-30 | 2012-06-06 | Novartis AG | Compositions and methods of use for antibodies of c-met |
US7741273B2 (en) | 2006-04-13 | 2010-06-22 | Warsaw Orthopedic, Inc. | Drug depot implant designs |
CA2658612C (en) | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
WO2008028977A2 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
EP2086998B1 (en) * | 2006-10-11 | 2011-12-07 | Ablynx N.V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
ES2663512T3 (es) | 2007-05-24 | 2018-04-13 | Ablynx N.V. | Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos |
EP2014681A1 (en) * | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
WO2009042589A1 (en) | 2007-09-24 | 2009-04-02 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
US8603474B2 (en) | 2008-01-29 | 2013-12-10 | Ludwig Institute For Cancer Research, Ltd. | Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy |
BRPI0911984A2 (pt) | 2008-05-16 | 2016-09-20 | Ablynx Nv | sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos |
SI2285408T1 (sl) | 2008-06-05 | 2019-02-28 | Ablynx N.V. | Aminokislinska zaporedja usmerjena proti proteinom ovojnicam virusa in polipeptidi, ki zaporedja vsebujejo za zdravljenje virusnih bolezni |
EP2143735A1 (en) | 2008-07-10 | 2010-01-13 | Institut Pasteur | Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins |
US20110200525A1 (en) | 2008-10-09 | 2011-08-18 | Patz Jr Edward F | Vhh antibody fragments for use in the detection and treatment of cancer |
KR20110079693A (ko) | 2008-10-29 | 2011-07-07 | 와이어쓰 엘엘씨 | 단일 도메인 항원 결합 분자의 정제 방법 |
MA33221B1 (fr) * | 2009-03-27 | 2012-04-02 | Glaxo Group Ltd | Fusions de médicament et conjugués afférents |
EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
EA201290525A1 (ru) | 2009-12-18 | 2013-01-30 | Санофи | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения |
JP5826194B2 (ja) | 2010-03-03 | 2015-12-02 | アブリンクス ナームローゼ フェンノートシャップ | 二パラトープ性a−ベータ結合ポリペプチド |
EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
WO2012042026A1 (en) * | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
US20150344568A1 (en) | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
PL2723771T3 (pl) * | 2011-06-23 | 2020-04-30 | Ablynx Nv | Białka wiążące albuminy surowicy |
KR20220114104A (ko) | 2011-06-23 | 2022-08-17 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
CA2845029A1 (en) | 2011-08-17 | 2013-02-21 | Glaxo Group Limited | Modified proteins and peptides |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
-
2012
- 2012-06-14 PL PL12727658T patent/PL2723771T3/pl unknown
- 2012-06-14 EP EP12727658.2A patent/EP2723771B1/en active Active
- 2012-06-14 ES ES12727658T patent/ES2759936T3/es active Active
- 2012-06-14 IN IN414CHN2014 patent/IN2014CN00414A/en unknown
- 2012-06-14 CN CN201280030647.8A patent/CN103619878B/zh active Active
- 2012-06-14 EP EP18205150.8A patent/EP3466972A1/en active Pending
- 2012-06-14 CA CA2839779A patent/CA2839779C/en active Active
- 2012-06-14 JP JP2014516279A patent/JP6324887B2/ja active Active
- 2012-06-14 LT LT12727658T patent/LT2723771T/lt unknown
- 2012-06-14 EP EP23159592.7A patent/EP4218933A1/en active Pending
- 2012-06-14 WO PCT/EP2012/061304 patent/WO2012175400A1/en active Application Filing
- 2012-06-14 SI SI201231696T patent/SI2723771T1/sl unknown
- 2012-06-14 AU AU2012271974A patent/AU2012271974B2/en active Active
- 2012-06-14 PT PT127276582T patent/PT2723771T/pt unknown
- 2012-06-14 US US14/128,719 patent/US9573992B2/en active Active
- 2012-06-14 HU HUE12727658A patent/HUE047238T2/hu unknown
- 2012-06-14 DK DK12727658T patent/DK2723771T3/da active
- 2012-06-14 CN CN201610392570.9A patent/CN106046168A/zh active Pending
- 2012-06-25 HR HRP20170535TT patent/HRP20170535T4/hr unknown
-
2017
- 2017-01-03 US US15/397,313 patent/US20170210789A1/en not_active Abandoned
-
2018
- 2018-04-11 JP JP2018076201A patent/JP6843090B2/ja active Active
-
2019
- 2019-11-29 HR HRP20192160TT patent/HRP20192160T1/hr unknown
- 2019-12-10 CY CY20191101299T patent/CY1122691T1/el unknown
-
2021
- 2021-02-22 JP JP2021026177A patent/JP7304375B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP3466972A1 (en) | 2019-04-10 |
ES2759936T3 (es) | 2020-05-12 |
HRP20170535T1 (hr) | 2017-06-16 |
WO2012175400A1 (en) | 2012-12-27 |
US20140228546A1 (en) | 2014-08-14 |
JP6843090B2 (ja) | 2021-03-17 |
DK2723771T3 (da) | 2019-12-02 |
JP2014520129A (ja) | 2014-08-21 |
US20170210789A1 (en) | 2017-07-27 |
CN103619878A (zh) | 2014-03-05 |
AU2012271974A1 (en) | 2013-12-12 |
EP4218933A1 (en) | 2023-08-02 |
PL2723771T3 (pl) | 2020-04-30 |
JP7304375B2 (ja) | 2023-07-06 |
EP2723771B1 (en) | 2019-09-11 |
SI2723771T1 (sl) | 2019-12-31 |
CN106046168A (zh) | 2016-10-26 |
AU2012271974B2 (en) | 2017-01-12 |
JP6324887B2 (ja) | 2018-05-16 |
HRP20170535T4 (hr) | 2022-08-19 |
LT2723771T (lt) | 2019-12-10 |
PT2723771T (pt) | 2019-12-11 |
US9573992B2 (en) | 2017-02-21 |
EP2723771A1 (en) | 2014-04-30 |
CN103619878B (zh) | 2016-10-26 |
IN2014CN00414A (hr) | 2015-04-03 |
CA2839779C (en) | 2020-10-06 |
CA2839779A1 (en) | 2012-12-27 |
CY1122691T1 (el) | 2021-03-12 |
JP2021088585A (ja) | 2021-06-10 |
HUE047238T2 (hu) | 2020-04-28 |
JP2018127478A (ja) | 2018-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20192160T1 (hr) | Vezujući proteini serumskog albumina | |
US20230050615A1 (en) | Improved serum albumin binding immunoglobulin single variable domains | |
HRP20191704T1 (hr) | Multispecifična protutijela | |
HRP20200464T1 (hr) | Metoda modifikacije polipeptida za pročišćavanje polipeptidnih multimera | |
US11414481B2 (en) | Serum albumin binders | |
AU2022279373A1 (en) | Improved immunoglobulin variable domains | |
WO2021244089A1 (zh) | 新型冠状病毒(sars-cov-2)刺突蛋白结合分子及其应用 | |
Behdani et al. | Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor | |
HRP20210364T1 (hr) | Anti-gitr antitijela i postupci za njihovu primjenu | |
HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
JP2018537421A5 (hr) | ||
SI2573121T1 (en) | IL-4 and / or IL-13 binding antibodies and their uses | |
Arbabi-Ghahroudi | Camelid single-domain antibodies: promises and challenges as lifesaving treatments | |
JP2017529067A5 (hr) | ||
WO2006068953A3 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
JP2020500510A5 (hr) | ||
US20230257457A1 (en) | Anti-p53 antibodies | |
EA028804B1 (ru) | Гетеродимерные иммуноглобулины | |
JP2012520679A5 (hr) | ||
HRP20240005T1 (hr) | Multispecifični mutirani fab fragmenti protutijela | |
JP2012518425A5 (hr) | ||
WO2007070432A3 (en) | Binding proteins specific for insulin-like growth factors and uses thereof | |
RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
JP2020195399A (ja) | Kv1.3結合免疫グロブリン |